Protara Therapeutics Inc

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GreenLight Biosciences Holdings PBC

Nextdoor

BitNile Holdings

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the American Society of Clinical Oncology Annual Meeting being held in Chicago, Illinois and virtually from June 3 through June 7, 2022. The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

- Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer -

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has dosed the first patient in ADVANCED-1, its Phase 1 clinical trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

The average of price targets set by Wall Street analysts indicates a potential upside of 687.9% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect?

- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way -

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer.

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete –

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protara's new General Counsel.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

TARA Stock: Why The Price Increased This Past Week

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 9% during intraday trading today. This is why it happened.

TARA Stock: Why It Increased Today

Protara Therapeutics (TARA) stock is heading higher on Tuesday following some major news from the FDA concerning clinical trials. The post 11 Things to Know About Protara Therapeutics as TARA Stock Soars on Big FDA News appeared first on InvestorPlace.

11 Things to Know About Protara Therapeutics as TARA Stock Soars on Big FDA News

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

Biopharma Stock Skyrockets on FDA Approval

Protara Therapeutics Inc (NASDAQ: TARA) is trading higher Tuesday after the company announced FDA clearance of the Investigational New Drug application for TARA-002 for the treatment of non-muscle invasive bladder cancer. Protara Therapeutics expects to begin a Phase 1 clinical trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer by the end of 2021.

Why Protara Therapeutics Stock Is Rising Today

- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End -

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held in a virtual setting on Wednesday, September 22, 2021 at 12:25pm ET.

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End -

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of Directors. Dr. Huang, an experienced biotech executive and proven leader throughout the development lifecycle of multiple oncology therapeutics globally, currently serves as Chief Medical Officer, Hematology at BeiGene, Ltd.

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

Inovio Pharmaceuticals

Novavax

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Data: Novavax, which is in the final legs of completing the COVID-19 vaccine race, is moving on success in another arena.

Why Novavax, Inovio, and Protara Are Moving Today

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) fell by over 7% pre-market. This is why it happened.

TARA Stock: Over 7% Decrease Pre-Market Explanation

Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations

News for Protara Therapeutics Inc Stock (TARA)